Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.

Literature DB >> 35358414

UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.

Ross J Mason¹, Karim Marzouk², Antonio Finelli³, Fred Saad⁴, Alan I So⁵, Philippe D Violette^6,7, Rodney H Breau⁸, Ricardo A Rendon¹.

Abstract

Entities: Chemical

Year: 2022 PMID： 35358414 PMCID： PMC9054332 DOI： 10.5489/cuaj.7851

Source DB: PubMed Journal: Can Urol Assoc J ISSN： 1911-6470 Impact factor: 2.052

× No keyword cloud information.

102 in total

1. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

Authors: Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja
Journal: Cancer Date: 2010-06-01 Impact factor: 6.860

2. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.

Authors: Claartje Gosselaar; Monique J Roobol; Stijn Roemeling; Theo H van der Kwast; Fritz H Schröder
Journal: Prostate Date: 2007-02-01 Impact factor: 4.104

Review 3. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Authors: Marco Auprich; Anders Bjartell; Felix K-H Chun; Alexandre de la Taille; Stephen J Freedland; Alexander Haese; Jack Schalken; Arnulf Stenzl; Bertrand Tombal; Henk van der Poel
Journal: Eur Urol Date: 2011-08-25 Impact factor: 20.096

4. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.

Authors: Mohamed H Radwan; Yan Yan; Jason R Luly; Robert S Figenshau; Steven B Brandes; Sam B Bhayani; Arnold D Bullock; Ye Liefu; Gerald L Andriole; Adam S Kibel
Journal: Urology Date: 2007-06 Impact factor: 2.649

5. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors: J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal: JAMA Date: 1993-08-18 Impact factor: 56.272

10. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

Authors: Sigrid Carlsson; Melissa Assel; Daniel Sjoberg; David Ulmert; Jonas Hugosson; Hans Lilja; Andrew Vickers
Journal: BMJ Date: 2014-03-28

1 in total

1. The CUA: Advocating for our patients.

Authors: Armen Aprikian
Journal: Can Urol Assoc J Date: 2022-10 Impact factor: 2.052

1 in total

UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.

1. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

2. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.

Review 3. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

4. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.

5. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

6. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

7. Assessing individual risk for prostate cancer.

8. Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012.

9. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

10. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

1. The CUA: Advocating for our patients.